Stockholm - Delayed Quote SEK

Hansa Biopharma AB (publ) (HNSA.ST)

39.34 0.00 (0.00%)

At close: October 30 at 12:59:39 PM GMT+1

Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

PR Newswire 8d ago

HNSA.ST
0.00%
HNSA@SS

SE0002148817
Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

PR Newswire 8d ago

HNSA.ST
0.00%
HNSA@SS

SE0002148817
Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering

PR Newswire 30d ago

HNSA.ST
0.00%
HNSA
Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

PR Newswire 3mo ago

HNSA.ST
0.00%
Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

PR Newswire 3mo ago

HNSA.ST
0.00%
SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma

GlobeNewswire 3mo ago

HNSA.ST
0.00%
Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

PR Newswire 5mo ago

HNSA.ST
0.00%
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026

PR Newswire 5mo ago

HNSA.ST
0.00%
SERB signs agreement to acquire Idefirix rights for $133.6m

Hospital Management 5mo ago

HNSA.ST
0.00%
SERB signs agreement to acquire Idefirix rights for $133.6m

Pharmaceutical Technology 5mo ago

HNSA.ST
0.00%
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA

PR Newswire 5mo ago

HNSA.ST
0.00%
SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million

GlobeNewswire 5mo ago

HNSA.ST
0.00%

U.S. markets closed

Hansa Biopharma AB (publ) (HNSA.ST)

Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026

SERB signs agreement to acquire Idefirix rights for $133.6m

SERB signs agreement to acquire Idefirix rights for $133.6m

Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA

SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million